| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Dioctanoylglycol does not have a specific biological target but functions as a lipid excipient. As a glycolipid, it can be incorporated into lipid-based formulations to improve the solubility and delivery of lipophilic drugs. Its structure, consisting of a hydrophilic ethylene glycol linker and two lipophilic octanoic acid chains, allows it to act as a surfactant and emulsifier. Its role is primarily formulation-based rather than pharmacologically active.
|
|---|---|
| ln Vitro |
Dioctanoylglycerol (dioctanoylglycerol) creates a longer-lasting diacylglycerol signal in platelets by inhibiting diacylglycerol phosphorylation (70–100% at 100 μM) [1].
In vitro, dioctanoylglycol is used in the preparation and characterization of lipid-based drug delivery systems. The compound's physical and chemical properties, including its solubility and compatibility with other lipids, are characterized for formulation development. The compound is not typically used in pharmacological activity assays but rather in studies of formulation stability, drug release, and cellular uptake of lipid-based carriers. |
| ln Vivo |
In vivo, dioctanoylglycol is used as a component of lipid-based formulations for drug delivery. The compound's in vivo behavior is formulation-dependent, and its role is to provide structural integrity and stability to the formulations. When administered, the lipid components are metabolized by esterases, releasing the constituent fatty acids. Its in vivo effects are related to the delivered drug rather than the lipid itself.
|
| Enzyme Assay |
The in vitro assays for dioctanoylglycol typically involve formulation characterization. Lipid-based formulations containing the compound are prepared using standard methods. Particle size is measured by dynamic light scattering (DLS), and drug encapsulation efficiency is determined. Drug release kinetics are assessed by dialysis. Stability studies are performed by monitoring particle size and drug leakage over time. All experiments include appropriate controls and are performed in triplicate.
|
| Cell Assay |
For in vitro cellular assays, lipid-based formulations containing dioctanoylglycol are incubated with cultured cells at varying lipid concentrations. Cellular uptake is assessed using fluorescently labeled lipids or encapsulated fluorescent markers by flow cytometry or confocal microscopy. Cytotoxicity is evaluated using MTT or CellTiter-Glo assays. For drug delivery studies, the efficacy of encapsulated drugs is compared to free drug controls. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo studies, lipid-based formulations containing dioctanoylglycol are typically administered to rodents via intravenous injection. Pharmacokinetic studies involve collecting blood samples at various time points and measuring drug or lipid concentrations by HPLC or LC-MS/MS. Biodistribution studies involve harvesting organs and measuring drug or lipid content. All animal procedures are conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of dioctanoylglycol as a lipid component are typically characterized in the context of the formulation. When administered, the lipid components are metabolized by esterases to release octanoic acid and ethylene glycol. The half-life of the lipid components in circulation depends on the formulation and surface modifications.
|
| Toxicity/Toxicokinetics |
The toxicology of dioctanoylglycol is primarily evaluated in the context of lipid-based formulations. As a lipid excipient, it is generally considered biocompatible and has low toxicity. In acute toxicity studies, the compound is well-tolerated at doses used for drug delivery. The compound is not genotoxic or carcinogenic. It is for research use only and is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
Dioctanoylglycol is a glycolipid compound used as a component in lipid-based drug delivery systems. It is a diester of ethylene glycol and octanoic acid. The compound is not approved for human use and is intended for research purposes only. It is available as a high-purity research reagent for laboratory use.
|
| Molecular Formula |
C18H34O4
|
|---|---|
| Molecular Weight |
314.46016
|
| Exact Mass |
314.246
|
| CAS # |
627-86-1
|
| Related CAS # |
54406-23-4
|
| PubChem CID |
3093
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.945g/cm3
|
| Boiling Point |
387.1ºC at 760 mmHg
|
| Flash Point |
179.8ºC
|
| Index of Refraction |
1.447
|
| LogP |
4.793
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
22
|
| Complexity |
248
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC(=O)OCCOC(=O)CCCCCCC
|
| InChi Key |
HTNFLUQQANUSLR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H34O4/c1-3-5-7-9-11-13-17(19)21-15-16-22-18(20)14-12-10-8-6-4-2/h3-16H2,1-2H3
|
| Chemical Name |
2-octanoyloxyethyl octanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~318.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.95 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1801 mL | 15.9003 mL | 31.8005 mL | |
| 5 mM | 0.6360 mL | 3.1801 mL | 6.3601 mL | |
| 10 mM | 0.3180 mL | 1.5900 mL | 3.1801 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
